402 related articles for article (PubMed ID: 19501911)
1. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin.
Xing R; Wang X; Zhang C; Zhang Y; Wang Q; Yang Z; Guo Z
J Inorg Biochem; 2009 Jul; 103(7):1039-44. PubMed ID: 19501911
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation of platinum anticancer drugs by apoferritin.
Yang Z; Wang X; Diao H; Zhang J; Li H; Sun H; Guo Z
Chem Commun (Camb); 2007 Sep; (33):3453-5. PubMed ID: 17700879
[TBL] [Abstract][Full Text] [Related]
3. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
4. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
5. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
6. Advances in platinum chemotherapeutics.
Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
[TBL] [Abstract][Full Text] [Related]
7. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
Oprea A; Bazzazi H; Kangarloo B; Wolff JE
Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
[TBL] [Abstract][Full Text] [Related]
8. Nanocapsules of platinum anticancer drugs: development towards therapeutic use.
Bryde S; de Kroon AI
Future Med Chem; 2009 Nov; 1(8):1467-80. PubMed ID: 21426060
[TBL] [Abstract][Full Text] [Related]
9. EXAFS and IR structural study of platinum-based anticancer drugs' degradation by diethyl dithiocarbamate.
Bouvet D; Michalowicz A; Crauste-Manciet S; Brossard D; Provost K
Inorg Chem; 2006 Apr; 45(8):3393-8. PubMed ID: 16602799
[TBL] [Abstract][Full Text] [Related]
10. Drug transporters of platinum-based anticancer agents and their clinical significance.
Burger H; Loos WJ; Eechoute K; Verweij J; Mathijssen RH; Wiemer EA
Drug Resist Updat; 2011 Feb; 14(1):22-34. PubMed ID: 21251871
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and administration of established platinum drugs.
O'Dwyer PJ; Stevenson JP; Johnson SW
Drugs; 2000; 59 Suppl 4():19-27. PubMed ID: 10864227
[TBL] [Abstract][Full Text] [Related]
12. Kinetic study on the reactions of platinum drugs with glutathione.
Hagrman D; Goodisman J; Souid AK
J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
[TBL] [Abstract][Full Text] [Related]
13. Application of fluorescence microscopy for investigation of cellular distribution of dinuclear platinum anticancer drugs.
Kalayda GV; Zhang G; Abraham T; Tanke HJ; Reedijk J
J Med Chem; 2005 Aug; 48(16):5191-202. PubMed ID: 16078838
[TBL] [Abstract][Full Text] [Related]
14. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
15. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
16. Cellular processing of platinum anticancer drugs.
Wang D; Lippard SJ
Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
Theile D; Kos M
Toxicol Lett; 2016 Feb; 242():47-52. PubMed ID: 26656794
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
20. [Platinum derivatives].
Sasaki Y
Nihon Rinsho; 2004 Dec; 62 Suppl 12():452-5. PubMed ID: 15658361
[No Abstract] [Full Text] [Related]
[Next] [New Search]